HilleVax, Inc. announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Franklin Templeton, Catalys Pacific, Samsara BioCapital, BVF Partners LP, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures. In connection with the financing, Patrick Heron, Managing Partner at Frazier, Elise Wang, Partner at Deerfield, and Shelley Chu, MD, PhD, Partner at Lightspeed, have joined the company's board of directors. HilleVax has also appointed five additional members to the board of directors, including: Julie Gerberding, MD, MPH.

Executive Vice President and Chief Patient Officer of Merck. Formerly, President of Merck Vaccines and Director of the U.S. Centers for Disease Control. Jeri Hilleman.

Chair of the Board of Omada Health and director and audit chair of public and private life sciences companies. Formerly, Chief Financial Officer of several public life sciences companies. Jaime Sepulveda, MD, DSc, MPH.

Executive Director of the University of California San Francisco (UCSF) Institute for Global Health Sciences. Formerly, Director of the National Institutes of Health of Mexico. Susan Silbermann.

Formerly Global President of Emerging Markets at Pfizer and Global President of Pfizer Vaccines. Rajeev Venkayya, MD. President of the Global Vaccine Business Unit at Takeda.

Formerly, Director of Vaccine Delivery at the Bill & Melinda Gates Foundation and Special Assistant to the President for Biodefense at the White House.